Abstract
Aim:
Chondrosarcoma is a malignant primary bone tumor that responds poorly to both chemotherapy and radiation therapy. The aim of the present study was to investigate the effect of alendronate, a bisphosphonate, on the invasion and migration of human chondrosarcoma cells (JJ012).
Methods:
JJ012 cells were treated with alendronate of various concentrations up to 100 μmol/L for a specified period, and then gelatin zymography and matrigel invasion assay was performed to study the effects of alendronate on matrix metalloproteinase (MMP)-2 activity and the invasion ability of JJ012 cells, respectively.
Results:
Our data showed that alendronate exerted a dose- and time-dependent inhibitory effect on the invasion and migration of JJ012 cells. Furthermore, gelatin zymography and RT-PCR showed that alendronate treatment decreased the activity and mRNA levels of MMP-2 in a concentration-dependent manner.
Conclusion:
Our findings suggest that alendronate may reduce MMP-2 secretion at the transcriptional and translational levels, and inhibit the invasion of chondrosarcoma cell. Therefore, alendronate may be a potential candidate for the systemic therapy of chondro-sarcomas, as well as other malignant diseases.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Terek RM, Schwartz GK, Devaney K, Glantz L, Mak S, Healey JH, et al. Chemotherapy and P-glycoprotein expression in chondrosarcoma. J Orthop Res 1998; 16: 585–90.
Yuan J, Dutton CM, Scully SP . RNAi mediated MMP-1 silencing inhibits human chondrosarcoma invasion. J Orthop Res 2005; 23: 1467–74.
Berend KR, Toth AP, Harrelson JM, Layfield LJ, Hey LA, Scully SP . Association between ratio of matrix metalloproteinase-1 to tissue inhibitor of metalloproteinase-1 and local recurrence, metastasis, and survival in human chondrosarcoma. J Bone Joint Surg Am 1998; 80: 11–7.
Kawata R, Shimada T, Maruyama S, Hisa Y, Takenaka H, Murakami Y . Enhanced production of matrix metalloproteinase-2 in human head and neck carcinomas is correlated with lymph node metastasis. Acta Otolaryngol 2002; 122: 101–6.
Pei Y, Harvey A, Yu XP, Chandrasekhar S, Thirunavukkarasu K . Differential regulation of cytokine-induced MMP-1 and MMP-13 expression by p38 kinase inhibitors in human chondrosarcoma cells: potential role of Runx2 in mediating p38 effects. Osteoarthritis Cartilage 2006; 14: 749–58.
Fong YC, Dutton CM, Cha SS, Garamszegi N, Sim FH, Scully SP . Absence of a correlation between the presence of a single nucleotide polymorphism in the matrix metalloproteinase 1 promoter and outcome in patients of chondrosarcoma. Clin Cancer Res 2004; 10: 7329–34.
Yoon SO, Park SJ, Yun CH, Chung AS . Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J Biochem Mol Biol 2003; 36: 128–37.
Yang SF, Hsieh YS, Lin CL, Hsu NY, Chiou HL, Chou FP, et al. Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients. Clin Chim Acta 2005; 354: 91–9.
Bjorklund M, Koivunen E . Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta 2005; 1755: 37–69.
Clezardin P . Anti-tumour activity of zoledronic acid. Cancer Treat Rev 2005; 31: 1–8.
Muller S, Migianu E, Lecouvey M, Kraemer M, Oudar O . Alendronate inhibits proliferation and invasion of human epidermoid carcinoma cells in vitro. Anticancer Res 2005; 25: 2655–60.
Cheng YY, Huang L, Lee KM, Li K, Kumta SM . Alendronate regulates cell invasion and MMP-2 secretion in human osteosarcoma cell lines. Pediatr Blood Cancer 2004; 42: 410–5.
Forsea AM, Muller C, Riebeling C, Orfanos CE, Geilen CC . Nitrogen-containing bisphosphonates inhibit cell cycle progression in human melanoma cells. Br J Cancer 2004; 91: 803–10.
Fromigue O, Lagneaux L, Body JJ . Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 2000; 15: 2211–21.
Heikkila P, Teronen O, Moilanen M, Konttinen YT, Hanemaaijer R, Laitinen M, et al. Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines. Anticancer Drugs 2002; 13: 245–54.
Lee MV, Fong EM, Singer FR, Guenette RS . Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 2001; 61: 2602–8.
Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW . Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000; 82: 1459–68.
Sonnemann J, Eckervogt V, Truckenbrod B, Boos J, Winkelmann W, van Valen F . The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro. Anticancer Drugs 2001; 12: 459–65.
Virtanen SS, Vaananen HK, Harkonen PL, Lakkakorpi PT . Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res 2002; 62: 2708–14.
Block JA, Inerot SE, Gitelis S, Kimura JH . Synthesis of chondrocytic keratan sulphate-containing proteoglycans by human chondrosarcoma cells in long-term cell culture. J Bone Joint Surg Am 1991; 73: 647–58.
Mosmann T . Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55–63.
Yang SF, Chu SC, Chiang IC, Kuo WF, Chiou HL, Chou FP, et al. Excessive matrix metalloproteinase-9 in the plasma of community-acquired pneumonia. Clin Chim Acta 2005; 352: 209–15.
Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J . Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000; 88: 2961–78.
Clezardin P . The antitumor potential of bisphosphonates. Semin Oncol 2002; 29: 33–42.
Green JR . Antitumor effects of bisphosphonates. Cancer 2003; 97: 840–7.
Heymann D, Ory B, Gouin F, Green JR, Redini F . Bisphosphonates: new therapeutic agents for the treatment of bone tumors. Trends Mol Med 2004; 10: 337–43.
Diel IJ . Antitumour effects of bisphosphonates: first evidence and possible mechanisms. Drugs 2000; 59: 391–9.
Lauer JL, Furcht LT, Fields GB . Inhibition of melanoma cell binding to type IV collagen by analogs of cell adhesion regulator. J Med Chem 1997; 40: 3077–84.
Author information
Authors and Affiliations
Corresponding author
Additional information
This study was supported by grants from China Medical University (No CMU-93-CM-15 and CMU-94-015) and China Medical University Hospital (No DMR-94-036 and DMR-95-067).
Rights and permissions
About this article
Cite this article
Lai, Tj., Hsu, Sf., Li, Tm. et al. Alendronate inhibits cell invasion and MMP-2 secretion in human chondrosarcoma cell line. Acta Pharmacol Sin 28, 1231–1235 (2007). https://doi.org/10.1111/j.1745-7254.2007.00607.x
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1111/j.1745-7254.2007.00607.x
Keywords
This article is cited by
-
In vitro effects of alendronate on fibroblasts of the human rotator cuff tendon
BMC Musculoskeletal Disorders (2020)
-
Cartilage tumours and bone development: molecular pathology and possible therapeutic targets
Nature Reviews Cancer (2010)
